GET THE APP

Macrocytosis anemia, Dyslipidemia and Hyperamylasemia in patients living with HIV in Cote dIvoire | Abstract
Scholars Research Library

Scholars Research Library

A-Z Journals

+44 7389645282

Der Pharmacia Lettre

Abstract

Macrocytosis anemia, Dyslipidemia and Hyperamylasemia in patients living with HIV in Cote dIvoire

Author(s): Lydie Boyvin, Angele Edjeme-Ake,Gervais M Boh, Armand Achi and Joseph Djaman

The destruction of the immune system, especially lymphocyte cells (or CD4), by HIV is responsible for hematopoietic and metabolic disorders (lipid disorders, amylase and lipodystrophy) caused by HIV- persistent viral replication and tritherapy increasing cardiovascular risk. Few studies were conducted in Côte D’Ivoire related to these disorders, while the country is the most affected by HIV / AIDS in West Africa (prevalence rate 3.4%). The aim of our study is to evaluate the hematological and biochemical profile (blood count, lipids, amylase) in Patients infected with HIV monitored at the Institute Pasteur of Cote D'Ivoire. This is an experimental prospective study to determine the biological parameters in the whole blood and serum samples of a cohort of 173 HIV positive adult subjects versus HIV negative the control subjects. After confirmation of HIV status (through a rapid screening test) of subjects included, CD4 lymphocytes, total cholesterol and its fractions and blood count were determined respectively by flow cytometry on FacsCalibur, on Cobas Integra 400 Plus and Sysmex XT-1800i. Anemia was significantly more common in PLHIV (72.26%) than in the controls population (26.59%) (P <0.0001). However, the high presence of macrocytosis anemia (18.50%) and isolated macrocytosis were observed (11.56%) versus (0% and 1.73%) in controls population respectively. They are lower HDL cholesterol (P <0.0001) in infected patients with a consequent increase in atherogenic index (AI) (P <0.0001) and hyperamylasemia (P <0.05) compared to controls subjects. The obtained results suggest a biological monitoring before and during antiretroviral therapy to prevent complications.